Skip to main content

Table 1 Comparison of baseline characteristics between the PF-ILD and non-PF-ILD groups among patients with fibrosing ILD

From: Progressive fibrosing interstitial lung disease: prevalence and clinical outcome

  Total PF-ILD Non-PF-ILD P-value
Number of patients 396 135 261  
Age, years 58.1 ± 10.6 58.7 ± 10.1 57.9 ± 10.8 0.474
Male 158 (39.9) 58 (43.0) 100 (38.3) 0.388
BMI, kg/m2 23.8 ± 3.3 24.3 ± 3.6 23.6 ± 3.1 0.074
Ever-smokers 163 (41.2) 56 (41.5) 107 (41.0)  > 0.999
ILD subtype 0.328
 iNSIP 76 (19.2) 20 (14.8) 56 (21.5)  
 HP 52 (13.1) 29 (21.5) 23 (8.8)  
 RA-ILD 168 (42.4) 58 (43.0) 110 (42.1)  
 SSc-ILD 54 (13.6) 18 (13.3) 36 (13.8)  
 SJS-ILD 46 (11.6) 10 (7.4) 36 (13.8)  
PFT, % predicted
 FVC 73.3 ± 16.6 70.5 ± 16.5 74.7 ± 16.5 0.016
 DLCO 62.4 ± 18.0 60.0 ± 16.7 63.6 ± 18.6 0.059
 TLC 74.9 ± 14.8 71.7 ± 13.6 76.6 ± 15.1 0.002
HRCT pattern 0.750
 UIP-like pattern 181 (45.7) 60 (44.4) 121 (46.4)  
 Non-UIP-like pattern 215 (54.3) 75 (55.6) 140 (53.6)  
Treatment 0.078
 Steroid ± IMa 365 (92.2) 129 (95.6) 236 (90.4)  
 No treatment 31 (7.8) 6 (4.4) 25 (9.6)  
  1. Data are expressed as mean ± standard deviation or number (%), unless otherwise indicated. aMycophenolate mofetil (n = 151), azathioprine (n = 110)
  2. PF progressive fibrosing, ILD interstitial lung disease, BMI body mass index, iNSIP idiopathic nonspecific interstitial pneumonia, HP hypersensitivity pneumonitis, PFT pulmonary function test; FVC forced vital capacity, DLCO diffusing capacity of the lung for carbon monoxide, TLC total lung capacity, HRCT high-resolution computed tomography, UIP usual interstitial pneumonia, IM immunosuppressant